Supplementary Figure S1 from ARID1A Loss plus CD8⁺ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

Zhaopei Liu; Lingkai Zhang; Kaifeng Jin; Han Zeng; Xiaohe Su; Yawei Ding; Jiupeng Sun; Yuzhen Wu; Hailong Liu; Yu Zhu; Le Xu; Weijuan Zhang; Zewei Wang; Yuan Chang; Jiejie Xu

doi:10.1158/1078-0432.30363436

October 15, 2025Open Access

Supplementary Figure S1 from ARID1A Loss plus CD8⁺ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

View Full Paper

Ask AI

Bookmark

Share

Key Points

Arid1A loss enhances cd8 t-cell infiltration, leading to more favorable clinical outcomes in urothelial carcinoma.
Patients with cd8 t-cell infiltration experienced significantly improved survival rates in association with arid1a loss.
Cohort studies from ZSHS and FUSCC indicate robust patterns linking arid1a alterations to immune response.
Findings may inform future therapeutic strategies targeting immune modulation in urothelial carcinoma.

Implication

Observational analysis shows that arid1a loss and cd8 t-cell presence improve clinical outcomes in urothelial carcinoma, suggesting potential therapeutic insights.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68f199c5de32064e504dcd2b https://doi.org/10.1158/1078-0432.30363436

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S1 from ARID1A Loss plus CD8⁺ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S1 from ARID1A Loss plus CD8⁺ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading